MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Barrette et al. examined how existing real-world evidence (RWE) guidance for hypothesis-evaluating treatment effectiveness (HETE) studies applies to non-HETE analyses.

Our goal at MTRC is to inform the decision-making of our clients and to support their market access activities. Below is a snapshot of our planned activities for the next two weeks. This can help our existing and prospective clients understand the potential scope of our support better. From the week of August 25th, we plan to work on 23 projects. Review the complete list of planned activities in this post.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its EU HTA Publications Digest. In a recent publication, Boers et al. introduced the Common European Classification Grid (CEUGrid-DMD) and an Evidence Matrix to harmonize the evaluation of digital medical devices (DMDs) across the EU.

In July 2025, the HTA body of Tuscany Regional Healthcare published nine rapid HTA reports (eight new assessments and one reassessment) of medical devices in the ENT, neurosurgery, ophthalmology, orthopedics, peripheral vascular, and surgical procedures fields.

On July 31, 2025, the Swiss Federal Statistics Office (UFS) released the systematic version of the Swiss classification of surgical interventions (CHOP) for 2026. The CHOP classification is now available in German and will come into force on January 1, 2026. Multiple new procedure codes were introduced in various fields, including the cardiovascular, ENT, extracorporeal treatments, interventional radiology, nephrology and urology, orthopedics, peripheral vascular, and radionucleide therapy.

In June-July 2025, Health Technology Wales (HTW) accomplished one full appraisal on implantable tibial neuromodulation devices for urinary incontinence. In addition, seven Med Tech-related Topic Exploration Reports were published in the e-health, diagnostic imaging, in-vitro diagnostics, neurology, and radiotherapy fields.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Sustainability Publications Digest. In a recent publication, van-Hove et al. analysed the carbon footprint of cataract surgery in England and the potential impact of adopting the NHS “Getting It Right First Time” (GIRFT) High Volume Low Complexity (HVLC) pathway.

On August 5, 2025, the Ministry of Labor, Health, Solidarity, and Families published the 2025 version of the List of Innovative Procedures Outside the Nomenclature (LAHN), which specifies tests funded under the innovative payment scheme for in-vitro diagnostics (RIHN). Tariffs for tests included in the LAHN were expected to decrease by 20% annually from January 1, 2025, except for those with a positive evaluation by the French National Authority for Health (HAS) in defined clinical indications. However, unlike previous edition, the 2025 LAHN does not specify tariffs. It introduces 14 new codes, which duplicate existing generic codes but are restricted to the clinical indications positively assessed by HAS. These new codes will be exempt from the annual tariff reduction.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Health Economic Publications Digest. In a recent publication, van Lieshout et al. examined how different stakeholders view the role of early health economic analyses (EHEA) in developing health innovations in the Netherlands.

In August 2025, the National Institute for Health and Care Excellence (NICE) announced two new projects within its Health Technology Assessment Innovation Laboratory (HTA Lab). The projects explore generative AI technologies in economic modelling and how AI can support and enhance NICE’s HTA processes through automation, predictive modeling, and reasoning systems.

MTRC shares the most relevant and impactful publications in the field of market access and HEOR for medical technologies in Europe through its Publications Digest. In a recent publication, Blanchard et al. explored the role of health technology assessment (HTA) in France beyond reimbursement and access to innovation.

In August 2025, the Common Catalog of Genetic and Genomic Tests of the National Health System in Spain was updated. Two sections with a total of 140 new genetic tests were introduced: one for bone diseases, including craniofacial anomalies, and another for kidney diseases and urogenital disorders. Furthermore, six new tests were added in pediatric oncohematology. Other changes concerned adult oncohaematology, hereditary metabolic, and mitochondrial diseases.